These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 4577261)

  • 1. Pilot study evaluating 1,3-bis(2-chloroethyl)-1-nitrosourea in the treatment of advanced ovarian carcinoma.
    Jorgensen EO; Malkasian GD; Webb MJ; Hahn RG
    Am J Obstet Gynecol; 1973 Jul; 116(6):769-70. PubMed ID: 4577261
    [No Abstract]   [Full Text] [Related]  

  • 2. 1,3-Bis (2-chloroethyl)-1-nitrosourea: effects on advanced ovarian carcinoma.
    Godfrey TE; King A; Rentschler R
    Am J Obstet Gynecol; 1973 Feb; 115(4):576-7. PubMed ID: 4685511
    [No Abstract]   [Full Text] [Related]  

  • 3. Phase II evaluation of BCNU and 5-FU in gastrointestinal carcinomas.
    Tormey DC; Gailani S; Leone L
    Oncology; 1974; 29(3):244-8. PubMed ID: 4415043
    [No Abstract]   [Full Text] [Related]  

  • 4. Proceedings: A controlled study of combined 1,3-bis-(2-chloroethyl)-1-nitrosourea and 5-fluorouracil therapy for advanced gastric and pancreatic cancer.
    Kovach JS; Moertel CG; Schutt AJ; Hahn RG; Reitemeier RJ
    Cancer; 1974 Feb; 33(2):563-7. PubMed ID: 4812773
    [No Abstract]   [Full Text] [Related]  

  • 5. Treatment of Hodgkin's disease and other cancers with 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Marsh JC; DeConti RC; Hubbard SP
    Cancer Chemother Rep; 1971 Dec; 55(5):599-606. PubMed ID: 4334161
    [No Abstract]   [Full Text] [Related]  

  • 6. Evaluation of cyclophosphamide (NSC-26271) and 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of patients with inoperable or disseminated lung cancer.
    Ahmann DL; Carr DT; Coles DT; Hahn RG
    Cancer Chemother Rep; 1972 Jun; 56(3):401-3. PubMed ID: 19051501
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination chemotherapy of bronchogenic carcinoma with cyclophosphamide (NSC-26271) and BCNU (NSC-409962).
    Curtis JE
    Cancer Chemother Rep; 1974; 58(6):883-8. PubMed ID: 4614897
    [No Abstract]   [Full Text] [Related]  

  • 8. Clinical evaluation of 1,3-bis(2-chloroethyl)-nitrosourea (BCNU; NSC-409962) with fluoxymesterone (NSC-12165) in the treatment of solid tumors.
    Reyes ES; Talley RW; O'Bryan RM; Gastesi RA
    Cancer Chemother Rep; 1973 Apr; 57(2):225-30. PubMed ID: 4582564
    [No Abstract]   [Full Text] [Related]  

  • 9. [On the therapy of lymphogranuloma. CCNU (1(2-chlorethyl)-3-cyclohexyl-1-nitrosourea) and BCNU (1,3-bis(2-chlorethyl)-1-nitrosourea) as well as BCNU combinations in Hodgkin's lymphogranuloma, stage 3 and 4].
    Brunner KW; Maurice P; Sonntag RW
    Schweiz Med Wochenschr; 1972 Oct; 102(43):1546-51. PubMed ID: 4647016
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination therapy for myelomatosis.
    Azam L; Delamore IW
    Br Med J; 1974 Dec; 4(5944):560-4. PubMed ID: 4611585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclophosphamide-induced immune thrombocytopenia in a patient with ovarian carcinoma successfully treated with intravenous gamma globulin.
    Mueller-Eckhardt C; Küenzlen E; Kiefel V; Vahrson H; Graubner M
    Blut; 1983 Mar; 46(3):165-9. PubMed ID: 6186321
    [No Abstract]   [Full Text] [Related]  

  • 12. Phase II study of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962) in the treatment of bronchogenic carcinoma.
    Olshin S; Siddiqui S; Firat D
    Cancer Chemother Rep; 1972 Apr; 56(2):259-61. PubMed ID: 5043228
    [No Abstract]   [Full Text] [Related]  

  • 13. [Endoxan in ovarian cancer].
    Campodónico I; Soldati A; Rodríguez A
    Rev Chil Obstet Ginecol; 1974; 39(3):87-9. PubMed ID: 4620179
    [No Abstract]   [Full Text] [Related]  

  • 14. Response of advanced breast cancer to two dosage regiments of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU; NSC-409962).
    Bonnet JD; Brownlee RW; Vaitkevicius VK; Talley RW
    Cancer Chemother Rep; 1973 Apr; 57(2):231-4. PubMed ID: 4742501
    [No Abstract]   [Full Text] [Related]  

  • 15. 1.3 Bis-(2 chloroethyl)-1-nitrosourea and streptozotocin chemotherapy.
    Lokich JJ; Chawla PL; Frei E
    Clin Pharmacol Ther; 1975 Mar; 17(3):374-8. PubMed ID: 123490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Chemotherapy in pancreatic carcinoma: 5 fluorouracil (5FU) and 1,3 bis-(2 chloretjyl)-1-nitrosourea (BCNU).
    Lokich J; Chawla PL; Brooks J; Frei E
    Ann Surg; 1974 Apr; 179(4):450-3. PubMed ID: 4815902
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical trial of BCNU (NSC-409962) combined with vincristine (NSC-67574) in disseminated gastrointestinal cancer and other neoplasms.
    Stolinsky DC; Pugh RP; Bohannon RA; Bogdon DL; Bateman JR
    Cancer Chemother Rep; 1974; 58(6):947-50. PubMed ID: 4614902
    [No Abstract]   [Full Text] [Related]  

  • 18. Nitrosoureas as single agents in the treatment of pulmonary cancer.
    Wolf J
    Cancer Treat Rep; 1976 Jun; 60(6):753-6. PubMed ID: 782697
    [No Abstract]   [Full Text] [Related]  

  • 19. The chemotherapy of brain tumors. Clinical experience with carmustine (BCNU) and vincristine.
    Fewer D; Wilson CB; Boldrey EB; Enot KJ; Powell MR
    JAMA; 1972 Oct; 222(5):549-52. PubMed ID: 4343318
    [No Abstract]   [Full Text] [Related]  

  • 20. Continuous low-dose cyclophosphamide (NSC-26271) therapy in advanced ovarian cancer.
    Mangioni C; Bolis G; Natale N; Morasca L
    Eur J Cancer (1965); 1976 May; 12(5):353-6. PubMed ID: 954793
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.